Trichlormethiazide

Summary

Trichlormethiazide (CHEMBL1054) is an approved small-molecule diuretic (ATC C03AA06); indicated across 1 condition including cardiovascular disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: C03AA06
• Indications: 1 condition
• Chemistry: 380.7 Da · C8H8Cl3N3O4S2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1054
Name	Trichlormethiazide
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	5560
ChEBI	CHEBI:9683
ATC	C03AA06
Molecular formula	C8H8Cl3N3O4S2
Molecular weight	380.7
InChIKey	LMJSLTNSBFUCMU-UHFFFAOYSA-N

SMILES: C1=C2C(=CC(=C1Cl)S(=O)(=O)N)S(=O)(=O)NC(N2)C(Cl)Cl

IUPAC name: 6-chloro-3-(dichloromethyl)-1,1-dioxo-3,4-dihydro-2H-1lambda6,2,4-benzothiadiazine-7-sulfonamide

ChEBI definition: A benzothiadiazine, hydrogenated at positions 2, 3 and 4 and substituted with an aminosulfonyl group at C-7, a chloro substituent at C-6 and a dichloromethyl group at C-3 and with S-1 as an S,S-dioxide. A sulfonamide antibiotic, it is used as a diuretic to treat oedema (including that associated with heart failure) and hypertension.

Pharmacological roles (ChEBI): diuretic, antihypertensive agent.

Also known as: Metahydrin, Naqua, NSC-61560, Trichlorex, Trichlormas, Trichlormethiazide, Trichlormethiazide component of naquival, Trichloromethiazide, Triclormetiazida, Trichlormethiazid, SID855703, TRICHLORMETHIAZIDE

Patent coverage: 3,284 distinct patent families (11,619 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 11,583 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 12 (assay-derived). Sample: Beta-lactamase, Carbonic anhydrase 2, Carbonic anhydrase 13, Carbonic anhydrase 7, Carbonic anhydrase 1, Carbonic anhydrase 6, Carbonic anhydrase 12, Carbonic anhydrase 14, Carbonic anhydrase 9, Carbonic anhydrase 4.

Bioactivity

ChEMBL activities: 13 potent at pChembl ≥ 5 of 14 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
CA7	8.1	Ki	7.9	nM	CHEMBL_ACT_2492000
CA9	7.06	Ki	87	nM	CHEMBL_ACT_2492007
CA2	7.04	Ki	91	nM	CHEMBL_ACT_2491958
CA5B	6.87	Ki	134	nM	CHEMBL_ACT_2491986
CA12	6.51	Ki	312	nM	CHEMBL_ACT_2492014
CA1	6.46	Ki	345	nM	CHEMBL_ACT_2491951
CA4	6.35	Ki	449	nM	CHEMBL_ACT_2491972
Q9D6N1	6.19	Ki	645	nM	CHEMBL_ACT_2492021
CA5A	6.12	Ki	763	nM	CHEMBL_ACT_2491979
CA2	5.77	Kd	1700	nM	CHEMBL_ACT_26047530
CA6	5.61	Ki	2459	nM	CHEMBL_ACT_2491993
CA2	5.58	Kd	2600	nM	CHEMBL_ACT_26047542
CA14	5.46	Ki	3450	nM	CHEMBL_ACT_2492028

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
cardiovascular disorder	4	MONDO:0004995	EFO:0000319

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).